An observational study in Hematopoietic Cell Transplantation Recipient, Leukemia and Solid Tumor, sponsored by Children's Oncology Group. Recruiting at 164 sites in 2 countries. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Children's Oncology Group · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Leukemia by Children's Oncology Group — 2 open to participants now, 4 under way, 1 of them phase 3. Leukemia · Children's Oncology Group.
Among the 98 studies in Leukemia by Children's Oncology Group, this one is the 2nd largest by planned enrollment of the 55 observational ones that give a count, is one of 3 that started in 2008, is one of 55 observational ones, and was the 45th registered.
2,382 studies on the registry are indexed under Leukemia; 252 are open to participants now.
Browse Leukemia studies →2 of the 98 studies in Leukemia by Children's Oncology Group are open now, in 4 countries. Recruiting first, the newest first:
Children's Oncology Group · Sites in United States, Australia, Canada and 1 more country
By country, each count listing its studies:
Of the 206 Leukemia studies recruiting now, 111 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 85 take children under 18; 24 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 15 · Phase 3 15
First in 1992; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25,000 is above the median of 142 across 332 observational studies indexed under Leukemia.
Median enrollment 120 across the 41 interventional studies, 60 across the 55 observational. Of the 92 that completed or were terminated, 6 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
Children's Oncology Group is the lead sponsor of 448 studies on the registry; 36 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 98 studies in Leukemia by Children's Oncology Group, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
PRIMARY OBJECTIVES:
I. To develop a mechanism for tracking and retaining patients enrolled on Children's Oncology Group (COG) protocols.
II. To maintain regular, lifetime contact with patients in order to obtain current identification and contact information, and self/parent-reported quality of life and health status.
III. To locate patients who are lost-to-follow-up for COG (or Legacy Group) protocols targeted for follow-up by the Long-Term Follow-Up Center (LTFC).
IV. To provide current patient contact information and self/parent-reported health status updates to the COG Statistics and Data Center (SDC) and to each patient's COG institution.
V. To facilitate collection of protocol-specific outcome data through collaboration with the LTFC Oversight Committee, the SDC, and the member institutions.
OUTLINE: This is an umbrella protocol for all long-term follow-up at COG institutions.
Within 3 months of enrollment on ALTE05N1, patients receive a packet introducing the Long-Term Follow-Up Center (LTFC). Patients are asked to complete a patient response form, verify information provided in packet, and update contact and health status information. The Health Status Update Form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. Patients may respond by use of postage prepaid envelopes, secure online form, or 24-hour toll-free telephone number. After initial contact, the LTFC will contact the patient annually.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Within 3 months of enrollment on ALTE05N1, patients receive a packet introducing the Long-Term Follow-Up Center (LTFC). Patients are asked to complete a patient response form, verify information provided in packet, and update contact and health status information. The Health Status Update Form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. Patients may respond by use of postage prepaid envelopes, secure online form, or 24-hour toll-free telephone number. After initial contact, the LTFC will contact the patient annually
Procedure: Assessment of Therapy Complications · Other: Questionnaire Administration
Complete patient response form and Health Status Update Form
Complete patient response form, Health Status Update Form (called the "Keep in Touch" form), and Quality of Life Questionnaire (PROMIS)
Percentage of patients enrolled
Time frame: Up to 20 years
Percentage of patients in which long-term (20+ years) contact is maintained
Time frame: Up to 20 years
Percentage of eligible patients located who were lost to follow-up
Time frame: Up to 20 years
Percentage of located patients enrolled
Differences between participants and non-participants will be examined annually, in terms of demographic (age, sex, ethnicity) and clinical characteristics (primary diagnosis, therapeutic protocol, time since diagnosis, treating institution).
Time frame: Up to 20 years
Collection of protocol-specific outcome data
Methods of statistical analysis to be used are those appropriate for analysis of cohort studies. Poisson regression (piece-wise exponential models) and Cox regression will be the primary methods of risk-factor analysis. When comparing study cohort with national rates, Poisson regression will be used. When the comparison is internal (ie, no use of national standard rates), Cox regression will be used.
Time frame: Up to 20 years
Collection of cumulative therapeutic exposure data
Time frame: Up to 20 years
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Showing the first 100 of 164 sites across 2 countries. Choose a country and city above to see the rest.
Started Jul 2008 (actual). Primary completion is estimated for Jan 2100, 1,098 months after the start.
Of 96 non-industry observational studies under Leukemia, half reached primary completion within 119 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 269. This study's planned 1,098 months is above that.
Counting every sponsor, half of 110 studies reached it within 119 months; a quarter within 40 and three quarters within 269.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.